FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Tirzepatide was removed from the shortages list a few weeks ago, leading to restrictions on the sale of compounded versions. However, the FDA has launched a review to check if the shortages have ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

If you've been scrolling through TikTok recently, you might have come across the "winter arc" trend — a sort of fresh take on the "new year, new me" mindset. The idea behind this social media ...

NEAR Protocol price analysis shows a rise to the $5.50 mark. NEAR price ROSE by over 1.2% at the time of writing. NEAR Protocol sought support and resistance at $5.50 and $6.00, respectively. Near ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.